Population
Patients with myocardial infarction undergoing reperfusion therapy, and animal models
Design
Review
Authors
Loading...
Stratifying reperfused patients by infarct size risk may overcome prior cardioprotection trial failures; leaves open translation amid comorbidities.
The failure to translate cardioprotective drugs into clinical practice is likely due to the dilution of trial data by including patients with small infarcts and the unaddressed interference of comorbidities like aging and diabetes.
Downey et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: